- CLSD stock price rose around 41% year-to-date to close at US$4.51 on June 21, 2021.
- ADIL to the enter gene-testing market after approval from the US patent office. The stock was trading at US$3.18, up 10.80%, at 11:27 am ET on June 22.
- MRKR stock price rose nearly 105% year-to-date to close at US$3.01 on June 21, 2021.
Penny stocks are favorites of retail investors because of their affordability. Penny stocks can be volatile and should be picked carefully. Penny stocks are companies that have a market cap of around US$60 million to US$300 million.
Here we explore three healthcare penny stocks that grabbed investors’ attention of late.
Clearside Biomedical, Inc. (NASDAQ: CLSD) is a biopharmaceutical company headquartered in Alpharetta, Georgia. It is engaged in developing treatment to prevent and restore vision in patients suffering from eye diseases.
Its market cap is US$263.7 million. Its total outstanding shares are 57,578,725. The company brought its IPO in 2016. Its revenue for the quarter ended March 31, 2021, was US$34,000, generated from licensing and other activities.
The company plans to launch its new drug XIPERE™ after receiving regulatory approval and license from the US drug authorities.
CLSD stock price rose around 41% year to date to close at US$4.51 on June 21, 2021. It was trading at US$4.536, up 0.58% at 12:11 pm ET on June 22, 2021.
Also Read: Why is 23andMe stock trending?
Adial Pharmaceuticals Inc. (NASDAQ: ADIL) is a clinical-stage bio-pharmaceuticals company headquartered in Charlottesville, Virginia. It develops drugs for treating addiction and related disorders. It developed a drug codenamed AD04 for treating Alcohol Use Disorder (AUD).
The company’s total outstanding shares (excluding convertible bonds, warrants and stock options) are 18,203,523, and its market capitalization is US$57.8 million. It brought its IPO in 2018.
ADIL has not received approval for its product yet, and so, it has not generated revenue from product sales in the March quarter. As of March 31, 2021, its accumulated deficit was US$36.4 million. ADIL had purchased Purnovate, Inc. in January this year. It plans to enter the gene-testing market after receiving the Notice of Allowance from the US patent office.
ADIL stock rose around 66% year to date to close at US$2.87 on June 21, 2021.
It was trading at US$3.18, up 10.80%, at 11:27 am ET on June 22, 2021.
Also Read: 10 Hot Penny Stocks To Explore In June
Marker Therapeutics, Inc. (NASDAQ: MRKR) is a Houston, Texas-based clinical-stage immune-oncology company. It develops vaccines for various diseases.
The company is currently developing two drugs for cancer treatment.
Its total listed share outstanding is 83,013,929, and its market capitalization is US$253.6 million.
MRKR has not generated any revenue from product sales yet. It reported a net loss of US$0.16 per share diluted in the quarter ended March 31, 2021.
The stock price rose nearly 105% year to date to close at US$3.01 on June 21, 2021. It was trading at US$3.055, up 1.50%, at 11:55 am ET on June 22, 2021.